Articles from EndoQuest Robotics, Inc.

EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved initiation of the next and final stage of its pivotal multicenter trial, the PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine). The PARADIGM Trial is an Investigational Device Exemption (IDE) study evaluating EndoQuest’s Endoluminal Surgical (ELS) System for use in endoscopic submucosal dissection (ESD) (Clinicaltrials.gov).

EndoQuest Robotics, Inc., a pioneering leader in endoluminal robotic surgical technology, today announced new initiatives as part of their collaboration with NVIDIA to integrate NVIDIA IGX Thor, an NVIDIA Blackwell-powered, enterprise-ready platform, into EndoQuest’s next-generation robotic system.